In addition to JAK-STAT aberrations, gain-of-function mutations in the RAS-MAPK pathway genes occurred in 3/14 ANKL patients, including those leading to the constitutive RAS activation (p.G12D and p.G13D) as well as a BRAF mutation (p.G469A). This evidence concerns the gene BRAF and aggressive NK-cell leukemia.